EIDOS THERAPEUTICS, INC. DIRECTOR INDEMNIFICATION AGREEMENTDirector Indemnification Agreement • May 25th, 2018 • Eidos Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [ ], 201[ ] by and between Eidos Therapeutics, Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”).
OFFICE LEASE BY AND BETWEEN a California limited partnership AS LANDLORD AND ElDOS THERAPEUTICS, INC., a Delaware corporation, AS TENANT PREMISES: San Francisco, CaliforniaOffice Lease • May 25th, 2018 • Eidos Therapeutics, Inc. • Pharmaceutical preparations • California
THIS OFFICE LEASE (this “Lease”) is made as of the 14th day of November, 2017, by and between 101 Montgomery Street Co., a California limited partnership (“Landlord”), and Eidos Therapeutics, Inc., a Delaware corporation (“Tenant”).
INTERCOMPANY SERVICES AGREEMENTIntercompany Services Agreement • May 25th, 2018 • Eidos Therapeutics, Inc. • Pharmaceutical preparations • California
This INTERCOMPANY SERVICES AGREEMENT (this “Agreement”), dated May 1, 2017 and effective as of May 1, 2017 (the “Effective Date”), is made and entered into by and between BridgeBio Services Inc., a Delaware corporation (the “Provider”), and Eidos Therapeutics, Inc., a Delaware corporation (the “Recipient”). The Provider and the Recipient may be referred to collectively herein as the “Parties” and each, a “Party.”
QB3@953 Sublease Agreement (the “Agreement”)Sublease Agreement • May 25th, 2018 • Eidos Therapeutics, Inc. • Pharmaceutical preparations
QB3 Incubator Partners, LP (“Landlord”) and Eidos Therapeutics, Inc., a State of Delaware C-Corporation (“Tenant”) agree as follows:
EIDOS THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • May 25th, 2018 • Eidos Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 29th day of March, 2018, by and among Eidos Therapeutics, Inc. a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 5.9 hereof.
S09-398 : CKC EXCLUSIVE (EQUITY) AGREEMENT CONFIDENTIALExclusive (Equity) Agreement • May 25th, 2018 • Eidos Therapeutics, Inc. • Pharmaceutical preparations • California
This Exclusive (Equity) Agreement (this “Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Eidos Therapeutics, Inc. (“Eidos”), a corporation having a principal place of business at 12354 Skyline Boulevard, Woodside, CA 94062, is effective on the 10th day of April, 2016 (“Effective Date”).
BONUS AGREEMENTBonus Agreement • May 25th, 2018 • Eidos Therapeutics, Inc. • Pharmaceutical preparations • California
This bonus agreement (this “Agreement”) is entered into as of April 26, 2018 (the “Effective Date”) by and between Eidos Therapeutics, Inc. (the “Company”) and Neil Kumar (the “Executive”). All capitalized terms set forth below and not defined shall have the respective meanings set forth in Section 4 of this Agreement.
